GlassScriptPhysician profile
Yiping Xing
NPI 1942799085
$2,948.44
in general payments reported to CMS, 2019-2025
24 companies · $908 in 2025
The $908 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $297 · 2023: $843 · 2024: $900 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,547 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.93 |
| Education | $104.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $448.88 | 2023-2025 | Dupixent, Libtayo |
| Abbvie INC. | $439.46 | 2022-2025 | |
| Incyte Corporation | $296.73 | 2022-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $262.96 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $204.27 | 2023-2024 | |
| Pfizer INC. | $183.11 | 2023-2025 | |
| Janssen Biotech, INC. | $172.73 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Arcutis Biotherapeutics, INC. | $140.41 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $108.95 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $98.67 | 2022-2025 | |
| Convatec INC. | $96.10 | 2022 | |
| Amgen INC. | $94.35 | 2023-2025 | Otezla, Otezla |
| Verrica Pharmaceuticals INC. | $78.21 | 2023 | Ycanth |
| Leo Pharma INC. | $51.28 | 2025 | Adbry |
| Organon LLC | $50.01 | 2025 | Vtama |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.21 | 2024 | Spevigo |
| Galderma Laboratories, L.P. | $32.27 | 2024-2025 | Aklief, Nemluvio |
| Dermavant Sciences, INC. | $25.23 | 2022 | |
| Csl Behring | $23.63 | 2025 | Hizentra |
| Pharming Healthcare, INC. | $21.75 | 2025 | Ruconest |
| Fresenius Kabi USA, LLC | $21.41 | 2023 | |
| Biofrontera INC. | $20.80 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $17.48 | 2025 | Bimzelx |
| Blueprint Medicines Corporation | $16.54 | 2025 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yiping Xing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.